Synergistic cytotoxic effect of sulindac and pyrrolidine dithiocarbamate against ovarian cancer cells

Oncology Reports

Volumn 27, Issue 4, 2012, Pages 1245-1250

  Jakubowska Mućka, Anna ^a   Sieńko, Jacek ^b   Zapała, Łukasz ^b   Wolny, Rafał ^b   Lasek, Witold ^b  

^a Institute of Oncology   (Russian Federation)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Apoptosis; Ovarian cancer; Pyrrolidine dithiocarbamate; Sulindac

Indexed keywords

PROSTAGLANDIN SYNTHASE; PYRROLIDINE DITHIOCARBAMATE; SULINDAC;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE ARREST; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; G0 PHASE; HUMANS; NF-KAPPA B; OVARIAN NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRROLIDINES; SULINDAC; THIOCARBAMATES; TIME FACTORS;

EID: 84856562693     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1639     Document Type: Article

References (40)

1. Gubbels JAA, Claussen N, Kapur AK, Connor JP and Patankar MS: The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res 3: 8-11, 2010.
2. Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, Rixe O, Ringeisen F, Tisseron Carrasco A and Lhomme C: Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecol Oncol 116: 157-162, 2010.
3. Pectasides D, Pectasides E, Papaxoinis G, Psyrri A, Pliarchopoulou K, Koumarianou A, Macheras A, Athanasas G, Xiros N and Economopoulos T: Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel-pretreated ovarian carcinoma. Gynecol Oncol 118: 52-57, 2010.
4. Ledermann JA and Raja FA: Targeted trials in ovarian cancer. Gynecol Oncol 119: 151-156, 2010.
5. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C and Meyskens F: Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10: 501-507, 2009.
6. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL and Shore RE: Aspirin and epithelial ovarian cancer. Prev Med 33: 682-687, 2001. (Pubitemid 34101895)
7. Sporn MB and Hong WK: Concomitant DFMO and sulindac chemoprevention of colorectal adenomas: a major clinical advance. Nat Clin Pract Oncol 5: 628-629, 2008.
8. Verheul HMW, Panigrahy D, Yuan J and D'Amato RJ: Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br J Cancer 79: 114-118, 1999. (Pubitemid 28566935)
9. Uddin S, Ahmed M, Hussain A, Assad L, Al-Dayel F, Bavi P, Al-Kuraya KS and Munkarah A: Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer 126: 382-394, 2010.
10. Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myers RB, Talley LI, Partridge EE and Grizzle WE: Effects of non-steroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 8: 202-209, 2002. (Pubitemid 34101479)
11. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK and DuBois RN: Cyclooxygenase-1 is overexpressed and promotes angiogenic factor production in ovarian cancer. Cancer Res 63: 906-911, 2003. (Pubitemid 36278417)
12. Munkarah A and Ali-Fehmi R: COX-2: a protein with an active role in gynecological cancers. Curr Opin Obstet Gynecol 17: 49-53, 2005. (Pubitemid 40315264)
13. Andrews P, Zhao X, Allen J, Li F and Chang M: A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother Pharmacol 61: 203-214, 2008. (Pubitemid 350160319)
14. Yip-Schneider MT, Wu H, Ralstin M, Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H, Sweeney CJ and Schmidt CM: Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther 6: 1736-1744, 2007. (Pubitemid 46954050)
15. Kunte DP, Wali RK, Koetsier JL and Roy HK: Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase. Mol Cancer Ther 7: 1797-1806, 2008.
16. Marotta A, Parhar K, Hundal R, Duronio V and Salh B: Differential targeting of protein kinase B in cell death induced by sulindac and its metabolite sulindac sulfide. Int J Oncol 28: 1471-1479, 2006.
17. Karl T, Seibert N, Stohr M, Osswald H, Rosl F and Finzer P: Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett 245: 103-111, 2007. (Pubitemid 44959344)
18. Song Z, Tong C, Liang J, Dockendorff A, Huang C, Augenlicht LH and Yang W: JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo. Eur J Pharmacol 560: 95-100, 2007. (Pubitemid 46341306)
19. Kim JS, Baek SJ, Sali T and Eling TE: The conventional non-steroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther 4: 487-493, 2005. (Pubitemid 40443934)
20. Nikitakis NG, Hebert C, Lopes MA, Reynolds MA and Sauk JJ: PPARγ-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. Int J Cancer 98: 817-823, 2002. (Pubitemid 34286675)
21. Park JH, Kim EJ, Jang HY, Shim H, Lee KK, Jo HJ, Kim HJ, Yang SH, Jeong ET and Kim HR: Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol Rep 20: 379-384, 2008.
22. Flis S and Spławiński J: Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide. Anticancer Res 29: 435-442, 2009.
23. Barnes AP, Miller BE and Kucera GL: Cyclooxygenase inhibition and hyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells. Gynecol Oncol 104: 443-450, 2007. (Pubitemid 46135645)
24. Govindan R, Wang X, Baggstrom MQ, Burdette-Radoux S, Hodgson L, Vokes EE, Green MR and Cancer and Leukemia Group B: A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 3014. J Thorac Oncol 4: 220-226, 2009.
25. Sinibaldi VJ, Elza-Brown K, Schmidt J, Eisenberger MA, Rosenbaum E, Denmeade SR, Pili R, Walczak J, Baker SD and Zahurak M: Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. Am J Clin Oncol 29: 395-398, 2006. (Pubitemid 44197546)
26. Oh DH, Bang JS, Choi HM, Yang HI, Yoo MC and Kim KS: Fetal bovine serum requirement for pyrrolidine dithiocarbamate-induced apoptotic cell death of MCF-7 breast tumor cells. Eur J Pharmacol 649: 135-139, 2010.
27. Chen D, Peng F, Cui QC, Danie KG, Orlu S, Liu J and Dou QP: Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front Biosc 10: 2932-2939, 2005. (Pubitemid 40910532)
28. Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD and Coffey RJ: Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPβ. Nat Med 3: 1233-1241, 1997. (Pubitemid 27508824)
29. Morais C, Gobe G, Johnson DW and Healy H: Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma. Apoptosis 14: 412-425, 2010.
30. Liu GH, Wang SR, Wang B and Kong BH: Inhibition of nuclear factor-κB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. Int J Gynecol Cancer 16: 1777-1782, 2006. (Pubitemid 44470035)
31. Gu JW, Young E, Busby B, Covington J, Tan W and Johnson JW: Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis and growth of breast cancer in female mice. Cancer Biol Ther 8: 514-521, 2009.
32. Jakubowska-Mucka A, Sienko J, Switaj T, Golab J and Lasek W: Antitumor effects of sulindac in ovarian cancer cell cultures. Ginekol Pol 82: 195-199, 2011 (In Polish).
33. Chou TC and Talalay P: Quantitive analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
34. Seo AM, Hong SW, Shin JS, Park IC, Hong NJ, Kim DJ, Lee WK, Lee WJ, Jin DH and Lee MS: Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKβ. Apoptosis 14: 913-922, 2009.
35. Yamamoto Y, Yin MJ, Lin KM and Gaynor RB: Sulindac inhibition activation of the NF-κB pathway. J Biol Chem 274: 27307-27314, 1999.
36. Nakanishi C and Toi M: Nuclear factor κB inhibitors as sensitizers to anticancer drugs. Nature Rev Cancer 5: 297-309, 2005. (Pubitemid 40488635)
37. Nai YJ, Jiang ZW, Wang ZM, Li N and Li JS: Prevention of cancer cachexia by pyrrolidine dithiocarbamate (PDTC) in colon 26 tumor-bearing mice. JPEN J Parenter Enteral Nutr 31: 18-25, 2007. (Pubitemid 46036293)
38. O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M and Crown J: A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol 59: 79-87, 2007. (Pubitemid 44796105)
39. Moos PJ, Muskardin DT and Fitzpatrick FA: Effect of taxol and taxotere on gene expression in macrophages: induction of the prostaglandin H synthase-2 isoenzyme. J Immunol 162: 467-473, 1999. (Pubitemid 29018955)
40. Morais C, Gobe G, Johnson DW and Healy H: Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor. Angiogenesis 12: 365-379, 2009.